| Literature DB >> 26610602 |
Abstract
Building on recent knowledge that the specificity of the biological interactions of small molecule hydrophiles and lipophiles across microvascular and epithelial barriers, and with cells, can be predicted on the basis of their conserved biophysical properties, and the knowledge that biological peptides are cell membrane impermeant, it has been further discussed herein that cellular, and thus, nuclear function, are primarily regulated by small molecule hormone and peptide/factor interactions at the cell membrane (CM) receptors. The means of regulating cellular, and thus, nuclear function, are the various forms of CM Pressuromodulation that exist, which include Direct CM Receptor-Mediated Stabilizing Pressuromodulation, sub-classified as Direct CM Receptor-Mediated Stabilizing Shift Pressuromodulation (Single, Dual or Tri) or Direct CM Receptor-Mediated Stabilizing Shift Pressuromodulation (Single, Dual or Tri) cum External Cationomodulation (≥3+ → 1+); which are with respect to acute CM receptor-stabilizing effects of small biomolecule hormones, growth factors or cytokines, and also include Indirect CM- or CM Receptor-Mediated Pressuromodulation, sub-classified as Indirect 1ary CM-Mediated Shift Pressuromodulation (Perturbomodulation), Indirect 2ary CM Receptor-Mediated Shift Pressuromodulation (Tri or Quad Receptor Internal Pseudo-Cationomodulation: SS 1+), Indirect 3ary CM Receptor-Mediated Shift Pressuromodulation (Single or Dual Receptor Endocytic External Cationomodulation: 2+) or Indirect (Pseudo) 3ary CM Receptor-Mediated Shift Pressuromodulation (Receptor Endocytic Hydroxylocarbonyloetheroylomodulation: 0), which are with respect to sub-acute CM receptor-stabilizing effects of small biomolecules, growth factors or cytokines. As a generalization, all forms of CM pressuromodulation decrease CM and nuclear membrane (NM) compliance (whole cell compliance), due to pressuromodulation of the intracellular microtubule network and increases the exocytosis of pre-synthesized vesicular endogolgi peptides and small molecules as well as nuclear-to-rough endoplasmic reticulum membrane proteins to the CM, with the potential to simultaneously increase the NM-associated chromatin DNA transcription of higher molecular weight protein forms, secretory and CM-destined, mitochondrial and nuclear, including the highest molecular weight nuclear proteins, Ki67 (359 kDa) and Separase (230 kDa), with the latter leading to mitogenesis and cell division; while, in the case of growth factors or cytokines with external cationomodulation capability, CM Receptor External Cationomodulation of CM receptors (≥3+ → 1+) results in cationic extracellular interaction (≥3+) with extracellular matrix heparan sulfates (≥3+ → 1+) concomitant with lamellopodesis and cell migration. It can be surmised that the modulation of cellular, and nuclear, function is mostly a reactive process, governed, primarily, by small molecule hormone and peptide interactions at the cell membrane, with CM receptors and the CM itself. These insights taken together, provide valuable translationally applicable knowledge.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26610602 PMCID: PMC4660824 DOI: 10.1186/s12967-015-0707-6
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Conservation of small biomolecule, peptide or factor and non-small molecule non-peptide function
| Type | Sub-type | Example(s) | Cell membrane (CM) or CM receptor | Effect at cell membrane (CM) receptor | Intracellular result of effect |
|---|---|---|---|---|---|
| Small molecule | |||||
| Small molecule hydrophile | Neutral hydrophile | H2O, nitrogenous bases | CM receptor aqueous pore | n/a (subcellular interaction, including nuclear/mitochondrial) | CM receptor/nuclear/mitoch aqueous pore permeation → DNA/RNA |
| Neutral cationoneutral hydrophile | Apolar amino acids (i.e. valine, alanine, leucine, isoleucine, etc) | CM receptor aqueous pore | n/a (subcellular interaction, including nuclear/mitochondrial) | CM receptor/nuclear/mitoch aqueous pore permeation → RNA/proteins | |
| Cationic–anionic hydrophile | Neurotransmitter (glycine, GABA) (IS 1+ 1−) | CM receptor aqueous pore | Receptor aqueous pore non-cationomodulation (isomodulation) and CM non-depolarization | CM receptor aqueous pore permeation | |
| Anionic cationoneutral hydrophile | Neurotransmitter glutamate (IS 1− 1−) | Peri-CM/peri-CM receptor aqueous pore | Ca2+ pseudo-association | Vesicular non-auto-endocytosis | |
| Cationic hydrophile | Neurotransmitters norepinephrine (1+), acetylcholine (1+) | CM receptor aqueous pore | Receptor aqueous pore internal cationomodulation and CM depolarization | Depolarization | |
| Cationic hydrophile | Neurotransmitters norepinephrine (1+), acetylcholine (1+) | CM | Direct CM cationiomodulation (Poly IS 1+) | Vesicular endocytosis | |
| Cationic hydrophile | Histamine @ acidic pH (IS 1+ 1+) | CM | Direct CM cationiomodulation (2+) | Vesicular auto-endocytosis | |
| Small molecule hydro-lipophile | Simple cationic hydro-lipophile | Neurotransmitters dopamine (1+), seratonin (1+) and histamine (1+) | CM receptor protein | Receptor external cationiomodulation and CM non-depolarization | Non-depolarization |
| Simple cationic hydro-lipophile | Neurotransmitters dopamine (1+), seratonin (1+) and histamine (1+) | CM | Direct CM cationiomodulation (poly IS 1+) | Vesicular endocytosis | |
| Circumferentially polyhydroxylated/carbonylated hydro-lipophile [non-compact (>pore size)] | i.e. Ouabain | CM receptor alpha helix isophilic aqueous pore (i.e. Na/K ATPase) | Receptor external hydroxymodulation → (Pseudo) 3ary indirect shift pressuromodulation | CM interaction receptor endocytosis [mitogenesis] | |
| Circumferentially polyhydroxylated/carbonylated hydro-lipophile + exterior cationicity [non-compact (>pore size)] | i.e. Doxorubicin (1+) | CM receptor alpha helix isophilic aqueous pore (i.e. Na/K ATPase) | Receptor external hydroxymodulation | CM interaction receptor endocytosis and cationicity (1+)-mediated mitochondrial toxicity | |
| Small molecule lipophile | Small lipophile | i.e. Benzene, di.e.thyl ether | CM receptor aqueous pore | Mitochondrial membrane perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis |
| Asymmetric unihydroxylated lipophile (stable) | Cholesterol (3-hydroxycholesterol), i.e. Cholecalciferol (3-hydroxyvitamin D3) | CM | CM incorporopressuromodulation | Baseline Chromatin DNA Protein Synthesis/Exocytosis | |
| Asymmetric unihydroxylated lipophile (unstable) | i.e. Hexan-1-ol, retinol | CM | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Asymmetric polyhydroxylated lipophile (unstable) | i.e. Phorbol ester 12-O-Tetradecanoylphorbol-13-acetate (TPA) | CM | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA Protein Synthesis/exocytosis | |
| Asymmetric unicarboxylated lipophile (stable) | Saturated fatty acid → ester | CM | CM incorporopressuromodulation | Baseline chromatin DNA protein synthesis/exocytosis | |
| Asymmetric unicarboxylated lipophile (stable) | Polyunsaturated fatty acid → ester (i.e. omega-3/6) | CM | CM Incorporo-negativopressuromodulation | n/a | |
| Asymmetric unicarboxylated lipophile (unstable) | Non-fatty acid (i.e. retinoic acid) | CM | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Asymmetric polyhydroxylated sterol | Aldosterone, dexamethasone, cortisol | CM receptor protein | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Symmetric di or trihydroxylated/dicarbonylated sterol | Testosterone, estrogen, progesterone | CM receptor protein | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Symmetric dihydroxylated lipophile | i.e. Calcifediol (1,25-dihydroxyvitamin D3) | CM | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| PolyHydroxylated/carbonylated lipophile (compact) | i.e. 3-Isobutyl-1-methylxanthine (IBMX) | CM and CM receptor aqueous pore | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Circumferentially polyhydroxylated/carbonylated lipophile [non-compact (>pore size)] | i.e. Forskolin | CM receptor alpha helix isophilic aqueous pore | Receptor external hydroxymodulation → (pseudo) 3ary indirect shift pressuromodulation | CM interaction receptor endocytosis [mitogenesis] | |
| Circumferentially polyhydroxylated/carbonylated/etheroylated lipophile [non-compact (>pore size)] | i.e. Paclitaxel (taxol), colchicine | CM receptor alpha helices | Receptor external hydroxymodulation | CM interaction receptor endocytosis and microtubular network disruption | |
| Non-small molecule non-peptide | Polyphospholipid polysaccharide | Lipopolysaccharide (LPS) | CM | CM perturbomodulation → 1ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis |
| Peptide | Small (non-alpha non-beta helix) peptide | Atrial natriuretic peptide (anp) monomer (1+ IS 1+) | CM receptor protein monomer | Receptor external cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic (2+) CM interaction receptor endocytosis [mitogenesis] |
| Small (non-alpha non-beta helix) peptide | Bradykinin monomer (1–9 AAs) (1+ IS 1+ SS 1+) | CM receptor protein monomer | Receptor external cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic (2+) CM interaction receptor endocytosis [mitogenesis] | |
| Small (non-alpha non-beta helix) peptide | Des-Arg9 Bradykinin Monomer (1-8 AAs) (1+ IS 1+) | CM Receptor Protein Monomer | Receptor External Cationiomodulation (2+) → 3ary Indirect Shift Pressuromodulation | Cationic (2+) CM Interaction Receptor Endocytosis [Mitogenesis] | |
| Small (non-alpha non-beta helix) peptide | Sulfate neutralized lys-bradykinin (kallidin) monomer (1–10 AAs) (IS 3+ → 1+) | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Vasopressin arginine (anti-diuretic hormone: ADH) monomer (1+) | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Neurotensin monomer (1+) | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Angiotensin II monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Ps4 thyrotropin releasing hormone (TRH) monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Somatostatin (growth hormone release inhibiting peptide: ghrip) monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Small (non-alpha non-beta helix) peptide | Oxytocin monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix | Glucagon monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short 2-way beta helix | Adrenocorticotropic hormone (ACTH) monomer | CM receptor protein monomer → dimer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Long monoalpha helix | Parathyroid hormone (PTH)/PTH releasing peptide (PTHrP) monomer | CM receptor protein monomer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Long monoalpha helix-loop-short 2-way beta helix | Pro-ACTH Pro-opiomelanocortin (POMC) monomer | CM receptor protein monomer → dimer | Receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix | Adrenocorticotrophin releasing hormone/factor (CRH/F) monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix | Insulin monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix | Osteocalcin monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix | Insulin-like growth factor-1 (IGF1/II; somatomedin C) monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix | Prolactin (PRL) releasing hormone/factor (PRLRH/factor) monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix | Growth hormone releasing hormone/factor (GHRH/F) monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix | Gonadotropin releasing hormone/factor (GnRH/F) monomer | CM receptor protein dimer (2 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Interleukin-3 (IL-3) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Interleukin-7 (IL-7) monomer | CM Receptor Protein Dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Interleukin-12 (IL-12) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Interleukin-23 (IL-23) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Prolactin (PRL) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Growth hormone (GH) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Erythropoietin (Ep) monomer | CM receptor protein dimer (2 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Aligned multialpha helix | Interferon gamma (INF-g) homodimer | CM receptor protein trimer (3 su: 3 su: <3 su>) | Dual-to-tri receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monoalpha helix | Interleukin-2 (IL-2) monomer | CM receptor protein dimer (3 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monoalpha helix | Interleukin-6 (IL-6) monomer | CM receptor protein dimer (3 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Interleukin-4 (IL-4) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Interleukin-13 (IL-13) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Interleukin-5 (IL-5) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Interleukin-15 (IL-15) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Interleukin-20 (IL-20) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monobeta 2-way helix | Granulocyte monocyte-colony stimulating factor (GM-CSF) monomer | CM receptor protein dimer (4 su: 2 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix cum short monoalpha helix cum short loop | Leukemia inhibitory factor (LIF)/oncostatin (OSM) monomer | CM receptor protein dimer (5 su: 3 su) | Dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Semi-aligned multialpha helix-loop-short monoalpha helix-loop-short monobeta 2-way helix | Granulocyte-colony stimulating factor (G-CSF)/macrophage (mouse)-colony stimulating factor (M-CSF) homodimer | CM receptor protein dimer (5 su: 3 su) | dual receptor stabilizing shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix (neutral) cum compact loose non-aligned 3-way beta-X-2-way beta helix (cationic) | Sulfate neutralized interleukin-16 (IL-16) monomer (IS 3+ → 1+) | CM receptor protein (CD4) monomer | External cationiomodulation and receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix (neutral) cum compact loose aligned 3-way beta helix (cationic) | Sulfate neutralized macrophage inflammatory protein-1 beta (MIP-1 beta: CCL20) monomer (IS 3+ → 1+) | CM receptor protein (CCR5) monomer | External cationiomodulation and receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Short monoalpha helix (neutral) cum compact loose aligned 3-way beta helix (cationic) | Sulfate neutralized CCL3/CCL4/CCL5 (RANTES) monomer (IS 3+ → 1+) | CM receptor protein (CCR5) monomer | External cationiomodulation and receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Short angled monoalpha helix (neutral) cum compact loose aligned 3-way beta helix (cationic) | Sulfate neutralized SDF-1 (CXCL-12) monomer (IS 3+ → 1+) | CM receptor protein (CXCR4) monomer | External cationiomodulation and receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Short angled monoalpha helix (neutral) cum compact loose aligned 3.5-way beta helix (cationic) | Sulfate neutralized interleukin-8 (IL-8) monomer (IS 3+ → 1+) | CM receptor protein (CXCR1) monomer | External cationiomodulation and receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact loose non-aligned multibeta helix (cationic) [+/− alpha helix knob (neutral)] | Sulfate neutralized fibroblast growth factor (FGF-19/FGF-2) monomer ×2 (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein monomer (3 su) → dimer (3 su: 3 su) | External cationiomodulation and dual receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact loose non-aligned multibeta helix (cationic) [+/− alpha helix knob (neutral)] | Sulfate neutralized hepatocyte growth factor alpha (hgf alpha; scatter factor) monomer ×2 (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein monomer (3 su) → dimer (3 su: 3 su) | External cationiomodulation and dual receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact loose non-aligned multibeta helix (cationic) [+/− alpha helix knob (neutral)] | Sulfate neutralized epidermal growth factor (EGF) monomer ×2 (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein monomer (3 su) → dimer (3 su: 3 su) | External cationiomodulation and dual receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact loose non-aligned multibeta helix (cationic) [+/− alpha helix knob (neutral)] | Sulfate neutralized interleukin-1 alpha (IL-1 alpha) monomer ×2 (IS 3+ → 1+: is 3+ → 1+) | CM receptor protein monomer (3 su) → dimer (3 su: 3 su) | External cationiomodulation and dual receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact loose non-aligned multibeta helix (cationic) [+/− alpha helix knob (neutral)] | Sulfate neutralized interleukin-1 beta (il-1 beta) monomer ×2 (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein monomer (3 su) → dimer (3 su: 3 su) | External cationiomodulation and dual receptor stabilizing shift pressuromodulation | Extracellular matrix interaction and chromatin DNA protein synthesis/exocytosis | |
| Compact tight semi-aligned multibeta helix (cationic) | Tumor necrosis factor alpha (TNF alpha) homotrimer (SS 1+) | CM receptor protein trimer | Tri receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Compact tight aligned multibeta helix (cationic) | Adiponectin homotrimer (SS 1+) | CM receptor protein trimer | Tri receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Compact tight aligned multibeta helix (cationic) | RANKL homotrimer (SS 1+) | CM receptor protein trimer | Tri receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized thyroid stimulating hormone alpha and beta (TSH alpha and beta) heterodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized luteinizing hormone alpha and beta (lh alpha and beta) heterodimer (is 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized follicle stimulating hormone alpha and beta (fsh alpha and beta) heterodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized human chorionic gonadotropin alpha and beta (HCG alpha and beta) Heterodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized brain-derived neurotrophic factor (bdnf) homodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized nerve growth factor beta (NGFb) homodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) | Sulfate neutralized neurotrophins (nts) homodimer (IS 3+ → 1+: IS 3+ → 1+) | CM receptor protein trimer | Tri receptor stabilizing shift pressuromodulation and external cationiomodulation | Chromatin DNA protein synthesis/exocytosis and extracellular matrix interaction | |
| Aligned long multibeta helix (cationic) cum short monoalpha helix (neutral) | Transforming growth factor beta (TGF beta) homodimer (SS 1+) | CM receptor protein quatramer | Quad receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Aligned long multibeta helix (cationic) cum short monoalpha helix (neutral) | Bone morphogenic protein-2/7 (BMP-2/7) homodimer (SS 1+) | CM receptor protein quatramer | Quad receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Aligned long multibeta helix (cationic) cum short monoalpha helix (neutral) | Platelet derived growth factor-BB (PDGF-BB) homodimer (SS 1+) | CM receptor protein quatramer | Quad receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Aligned long multibeta helix (cationic) cum short angled monoalpha helix (neutral) | Placenta growth factor (PLGF) homodimer (SS 1+) | CM receptor protein quatramer | Quad receptor internal pseudo-cationomodulation → 2ary indirect shift pressuromodulation | Chromatin DNA protein synthesis/exocytosis [mitogenesis] | |
| Aligned long multibeta helix (cationic) cum short angled monoalpha helix (neutral) | Vascular endothelial growth factor-A (VEGF-A)/vascular permeability factor (VPF) homodimer (1+ IS 1+ SS 1+ IS 1+) | CM receptor protein quatramer | Quad receptor external cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic (2+) CM interaction receptor endocytosis → mitogenesis | |
| Compact loose non-aligned multibeta helix-intertwined-non-aligned multialpha helix | Diferric transferrin-(Fe3+ → Fe2+)2 monomers ×2 (3+ SS 3+: 3+ SS 3+ → 2+ SS 2+: 2+ SS 2+) | CM receptor protein (TfR) dimer | Fe2+ receptor external cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic diferric iron (Fe2+) CM interaction receptor endocytosis→ mitogenesis | |
| Long dualalpha helix (neutral) cum compact loose aligned beta helix cum multishort 2-way beta helix (cationic) | Hemochromatosis protein (HPE) monomers ×2 [(1+ IS 1+)n SS (1+ IS 1+)n] | CM receptor protein (TfR) dimer | Transient RSP; external beta helix CM receptor cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic diferric iron (Fe2+) cm interaction receptor endocytosis→ mitogenesis | |
| Short monoalpha helix-loop-short monoalpha helix-loop-short monoalpha helix (neutral) cum compact loose non-aligned 5-way beta-X-3-way beta helix (cationic) | Partially sulfate neutralized procollagen I peptide III C monomer (IS 4+ → 2+) | CM receptor protein dimer (3 su: 3 su) | Dual receptor external cationiomodulation (2+) → 3ary indirect shift pressuromodulation | Cationic (2+) CM interaction receptor endocytosis → mitogenesis | |
SS sufficient separation of 2+ cationicity in molecular space, which is important, as it precludes Heparan Sulfate neutralization of cationicity, that which requires the presence of >2+ charge insufficiently separated in molecular space
IS insufficient separation of 1+ cationicity in molecular space, which is important, as it precludes endocytosis, that which requires the presence of 2+ charge insufficiently separated in molecular space